| Zhang, Jian |
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI |
|
|
| Recruiting | 4 | 668 | RoW | Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic | Shenyang Northern Hospital | Percutaneous Coronary Intervention | 12/20 | 12/20 | | |
NCT04446819: Compression Gloves to Reduce Albumin-binding Paclitaxel Induced Peripheral Sensory and Motor Neurotoxicity (REMAINING) |
|
|
| Recruiting | 3 | 70 | RoW | Compression gloves | Fudan University | Peripheral Neuropathy | 01/22 | 06/22 | | |
NCT03388593: Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. |
|
|
| Recruiting | 3 | 1600 | RoW | rhNRG-1, Neucardin™, Placebo | Zensun Sci. & Tech. Co., Ltd. | Chronic Heart Failure | 02/26 | 02/26 | | |
TQB2450-III-09, NCT04964479: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) |
|
|
| Recruiting | 3 | 375 | RoW | TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection, Placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 12/22 | 03/23 | | |
NCT06143553: Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 168 | RoW | Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound) | Shanghai Yizhong Pharmaceutical Co., Ltd. | Metastatic Breast Cancer (MBC) | 12/25 | 12/25 | | |
NCT05346861: Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab |
|
|
| Recruiting | 3 | 240 | RoW | Trastuzumab plus chemotherapy, Trastuzumab in combination with pyrotinib plus chemotherapy | Fudan University | HER2-positive Breast Cancer, Metastatic Breast Cancer | 10/23 | 10/24 | | |
NCT05949801: Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure |
|
|
| Completed | 3 | 202 | RoW | Neucardin, Recombinant human Neuregulin-1 for Injection, Placebo, Excipients of recombinant human neuregulin-1 freeze dried for injection | Zensun Sci. & Tech. Co., Ltd. | Chronic Systolic Heart Failure | 08/24 | 10/24 | | |
| Recruiting | 3 | 224 | RoW | DB-1303/BNT323, T-DM1 | DualityBio Inc., BioNTech SE | HER2-positive Breast Cancer | 02/26 | 02/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
GenSci093-301, NCT06449027: Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects. |
|
|
| Not yet recruiting | 3 | 200 | RoW | T Leuprolide Injectable Emulsion, Tamoxifen Citrate Tablets, Leuprorelin Acetate Microspheres for Injection | Changchun GeneScience Pharmaceutical Co., Ltd. | Breast Cancer Subjects | 11/25 | 03/26 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
NCT06382142: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 3 | 406 | RoW | BL-B01D1, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-Negative Breast Cancer | 06/26 | 06/26 | | |
NCT06519370: FDA018-ADC Vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | FDA018-ADC, FDA018-Antibody-drug Conjugate, Eribulin, Halaven, Capecitabine, Xeloda, Gemcitabine, Gemzar, Vinorelbine, Navelbine | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Triple Negative Breast Cancer | 08/26 | 06/27 | | |
NCT06680921: A Study of SIM0270 Combined with Everolimus Vs. Treatment of Physician's Choice in Patients with ER+/HER2- Advanced Breast Cancer (SIMRISE) |
|
|
| Recruiting | 3 | 460 | RoW | SIM0270, Everolimus (Afinitor®), Exemestane tablets, Fulvestrant injection | Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing Zaiming Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 08/28 | 08/28 | | |
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects |
|
|
| Not yet recruiting | 3 | 400 | RoW | JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Breast Cancer | 04/25 | 03/29 | | |
| Active, not recruiting | 3 | 600 | Europe, Canada, US, RoW | Gotistobart, A humanized anti-CTLA4 IgG1 monoclonal antibody, ONC-392, BNT316, Docetaxel, Docefrez, Taxotere | OncoC4, Inc., BioNTech SE | Non Small Cell Lung Cancer | 06/26 | 06/27 | | |
| Not yet recruiting | 2/3 | 1800 | RoW | Blinatumomab (Group A), high-dose methotrexate, Venetoclax (nonRand Group), cyclophosphamide, vincristine, dexamethasone, Blinatumomab (Group B) | Institute of Hematology & Blood Diseases Hospital, China | Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL) | 12/29 | 06/31 | | |
NCT04303988: A Phase II Study of Triple-negative Breast Cancer Brain Metastases. |
|
|
| Recruiting | 2 | 35 | RoW | SHR-1316, HTI-1088, Bevacizumab, Avastin, Cisplatin/Carboplatin, Bobei | Fudan University | Breast Cancer | 12/24 | 05/25 | | |
NCT05354076: Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo |
|
|
| Recruiting | 2 | 30 | RoW | doxorubicin hydrochloride liposome injection | Fudan University | Advanced Malignant Tumors | 06/22 | 11/22 | | |
NCT04192903: Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Chidamide combined with Cisplatin | Fudan University | Triple-negative Breast Cancer | 06/22 | 06/22 | | |
TEMPLATE, NCT04913571: Tislelizumab in Combination With Eribulin for Patients With Metastatic Previously heaviLy-treAted TriplE-negative Breast Cancer：A Prospective Multiple-center Phase II Study |
|
|
| Not yet recruiting | 2 | 265 | RoW | Eribulin, Tislelizumab | Fudan University | Triple Negative Breast Cancer | 06/22 | 06/23 | | |
NCT04517292: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) |
|
|
| Not yet recruiting | 2 | 160 | RoW | Eribulin,cisplatin, Gemcitabine,cisplatin | Fudan University | Breast Cancer | 07/22 | 10/22 | | |
| Completed | 2 | 37 | RoW | HX008，Niraparib, HX008，Niraparib，Trastuzumab, HX008，Niraparib，Pyrrolitinib | Fudan University | Treatment Efficacy | 08/22 | 02/23 | | |
NCT04780347: Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Albumin-bound paclitaxel plus capecitabine, capecitabine | Fudan University | Breast Cancer | 12/22 | 02/23 | | |
NCT04745975: Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer |
|
|
| Recruiting | 2 | 100 | RoW | Personalized treatment guided by mini-PDX and RNA sequencing, Nab paclitaxel, Eribulin, Vinorelbine, Gemcitabine, Capecitabine | Fudan University | Triple Negative Breast Cancer | 01/23 | 01/23 | | |
NCT04778982: Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer |
|
|
| Terminated | 2 | 4 | RoW | KN026 combined with Palbociclib and Fulvestrant, combination | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2-positive Metastatic Breast Cancer | 03/23 | 03/23 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT06332300: An Exploratory Clinical Study of Adebelimumab in Combination With Famitinib and Chemotherapy in Patients With NSCLC |
|
|
| Withdrawn | 2 | 28 | RoW | Adebelimumab+Famitinib + FOLFIRI+Ariely | Jiangsu Province Nanjing Brain Hospital | NSCLC | 02/25 | 02/26 | | |
NCT06413615: A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 150 | RoW | FDA022-BB05 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/25 | 06/26 | | |
NCT06492005: A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer |
|
|
| Recruiting | 2 | 160 | RoW | 9MW2821, PD-1 inhibitior | Mabwell (Shanghai) Bioscience Co., Ltd. | Triple-Negative Breast Cancer | 07/26 | 07/27 | | |
NCT06471205: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 52 | RoW | BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Triple-negative Breast Cancer | 07/26 | 07/26 | | |
| Recruiting | 2 | 200 | RoW | Camrelizumab, PD-1 antibody, Gemcitabine, Gem, Induction Cisplatin, DDP, intensity-modulated radiotherapy, IMRT, Concurrent cisplatin | Wei Jiang, Wuzhou Red Cross Hospital, Guangxi Nanxishan Hospital, Laibin People's Hospital, Lingshan people's Hospital | Nasopharyngeal Carcinoma | 04/25 | 04/26 | | |
NCT06042894: A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 58 | RoW | BL-B01D1, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Breast Cancer | 12/25 | 12/25 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT05785728: A Study of DB-1202 Monotherapy in Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 150 | RoW | DB-1202 | DualityBio Inc. | Advanced Solid Tumor | 02/24 | 02/24 | | |
NCT04282031: A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer |
|
|
| Recruiting | 1/2 | 224 | RoW | BPI-1178, Fulvestrant, Letrozole | Beta Pharma (Suzhou) Co., Ltd. | Advanced Solid Tumor, HR+/HER2- Breast Cancer | 12/24 | 06/25 | | |
| Recruiting | 1/2 | 181 | US, RoW | MRG004A | Shanghai Miracogen Inc. | Advanced or Metastatic Solid Tumors | 04/24 | 06/25 | | |
NCT05048160: A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm |
|
|
| Recruiting | 1/2 | 272 | RoW | Intravenous Infusion | Mabwell (Shanghai) Bioscience Co., Ltd. | Advanced Malignant Neoplasm | 06/24 | 12/24 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05927779: Study of TFX06 in Women With Advanced Breast Cancer. |
|
|
| Recruiting | 1/2 | 74 | RoW | TFX06 tablet | Shenzhen Yangli Pharmaceutical Technology Co., Ltd | ER+, HER2- Advanced Breast Cancer, Metastatic Breast Cancer | 12/24 | 04/25 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
| Recruiting | 1/2 | 404 | US, RoW | Rina-S, PRO1184, Rinatabart sesutecan, GEN1184, Carboplatin, Bevacizumab, Pembrolizumab | Genmab | Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Breast Adenocarcinoma, Triple Negative Breast Cancer, Hormone Receptor-positive/Her2 Negative Breast Cancer | 04/26 | 10/26 | | |
NCT05301764: A Study of LVGN6051 Combined with Anlotinib in Patient with Soft Tissue Sarcoma |
|
|
| Recruiting | 1/2 | 65 | RoW | LVGN6051 and Anlotinib | Lyvgen Biopharma Holdings Limited | Soft Tissue Sarcoma | 03/25 | 10/25 | | |
NCT05803018: A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies |
|
|
| Recruiting | 1/2 | 32 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gynecological Malignant Tumor, Solid Tumor | 06/25 | 06/25 | | |
NCT05842785: TSN222 in Subjects With Advanced Solid Tumors or Lymphomas |
|
|
| Recruiting | 1/2 | 162 | RoW | Phase I dose escalation, Phase II-HNSCC, Phase II-Advanced melanoma, Phase II-solid tumors or lymphomas | Tyligand Bioscience (Shanghai) Limited | Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma | 06/25 | 06/26 | | |
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 902 | US, RoW | DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327 | DualityBio Inc., BioNTech SE | Advanced Solid Tumor | 06/25 | 06/25 | | |
| Recruiting | 1/2 | 208 | RoW | 9MW2821 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 12/25 | 12/25 | | |
NCT05416749: A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 216 | RoW | 8MW2311 | Mabwell (Shanghai) Bioscience Co., Ltd. | Solid Tumors | 03/26 | 03/26 | | |
NCT05463432: A Study of HR19024 in Subjects With Advanced Solid Tumor |
|
|
| Recruiting | 1a | 180 | RoW | HR19024 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 07/23 | 07/23 | | |
| Completed | 1 | 23 | RoW | Humanized Anti-HER2 Monoclonal Antibody Compound for Injection .R&D code: B002., Biological Products, Humanized Anti-HER2 Monoclonal Antibody Compound for Injection | Shanghai Pharmaceuticals Holding Co., Ltd | Recurrent Breast Cancer, Metastatic Breast Cancer | 04/22 | 04/22 | | |
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06299124: A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors |
|
|
| Recruiting | 1 | 40 | RoW | RGT-419B, Active drug | Regor Pharmaceuticals Inc. | Breast Cancer, Advanced Solid Tumor | 12/24 | 06/25 | | |
NCT04631835: Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 54 | RoW | HS-10352 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Breast Cancer | 04/23 | 08/23 | | |
NCT05221385: Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma |
|
|
| Terminated | 1 | 58 | RoW | Gentulizumab | Changchun GeneScience Pharmaceutical Co., Ltd. | Solid Tumor, Non-Hodgkin Lymphoma | 05/23 | 10/23 | | |
NCT06182735: CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma |
|
|
| Recruiting | 1 | 9 | RoW | Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells | Fudan University | Renal Cell Carcinoma | 01/25 | 01/25 | | |
NCT05078593: A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma |
|
|
| Completed | 1 | 18 | RoW | HLX26, Anti-LAG-3 Monoclonal Antibody | Shanghai Henlius Biotech | Solid Tumor, Adult, Lymphoma | 08/23 | 08/23 | | |
NCT05798533: Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03) |
|
|
| Recruiting | 1 | 6 | RoW | Neo-T, Neoantigen targeting T cells Suspension for Intravenous Infusion, Toripalimab, JS001, Tislelizumab, BGB-A317 | BGI, China, Fudan University, Shanghai 10th People's Hospital | Solid Tumor | 09/23 | 09/24 | | |
| Completed | 1 | 28 | RoW | AZD9833, AZD9833 with palbociclib, AZD9833 with everolimus | AstraZeneca | ER+, HER2-, Metastatic Breast Cancer | 09/23 | 09/23 | | |
NCT05972460: IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 108 | RoW | IMM2510, IMM2510 Injection | ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Zhejiang Cancer Hospital, Fudan University | Advanced Solid Tumors | 12/23 | 10/24 | | |
NCT05337657: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer |
|
|
| Recruiting | 1 | 10 | RoW | GB491+Letrozole | Genor Biopharma Co., Ltd. | Advanced Breast Cancer | 12/23 | 02/24 | | |
NCT06761651: A Study of TAVO412 in Patients with Cancer (TAVO412) |
|
|
| Recruiting | 1 | 50 | RoW | TAVO412 | Tavotek Biotherapeutics | Cancer | 01/26 | 10/26 | | |
NCT06172322: A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer |
|
|
| Recruiting | 1 | 42 | RoW | NTQ1062 with Fulvestrant | Nanjing Chia-tai Tianqing Pharmaceutical | HR Positive/HER-2 Negative Breast Cancer | 04/25 | 07/25 | | |
NCT05360368: HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 24 | RoW | HLX07, Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection | Shanghai Henlius Biotech | Solid Tumor | 12/23 | 02/24 | | |
| Recruiting | 1 | 177 | RoW | HS-20089 (Phase Ia：Dose escalation ), HS-20089 (Phase Ib: Dose expansion) | Shanghai Hansoh Biomedical Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
NCT05263180: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. |
|
|
| Recruiting | 1 | 30 | RoW | EMB-09 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Advanced Solid Tumor | 12/23 | 12/24 | | |
NCT05498597: AMT-151 in Patients With Selected Advanced Solid Tumours |
|
|
| Recruiting | 1 | 30 | RoW | AMT-151 | Multitude Therapeutics Inc., Tigermed Consulting Co., Ltd | Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma, Ovarian Cancer, Ovarian Carcinoma, Ovarian Epithelial Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Lung Adenocarcinoma, Triple Negative Breast Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Pleural Mesothelioma, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Mucinous Adenocarcinoma | 01/24 | 10/24 | | |
NCT06219356: A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas |
|
|
| Recruiting | 1 | 110 | RoW | GLB-002, GLB-A062-B | Hangzhou GluBio Pharmaceutical Co., Ltd. | Non-Hodgkin Lymphoma | 01/26 | 02/27 | | |
NCT04586335: Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. |
|
|
| Terminated | 1 | 24 | US, RoW | CYH33, Olaparib | Haihe Biopharma Co., Ltd. | Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer | 02/23 | 02/23 | | |
NCT05509790: A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer |
|
|
| Active, not recruiting | 1 | 17 | RoW | LY3484356 | Eli Lilly and Company | Breast Neoplasms | 02/24 | 12/25 | | |
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
| Recruiting | 1 | 12 | RoW | Cyclophosphamide + Fludarabine + Infusion of CAR-NKT Cells | Fudan University | Solid Tumor | 06/26 | 06/26 | | |
NCT04893759: A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors |
|
|
| Recruiting | 1 | 60 | RoW | Pelcitoclax, APG-1252 | Ascentage Pharma Group Inc. | Neuroendocrine Tumors | 06/24 | 06/25 | | |
NCT06536400: Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation |
|
|
| Recruiting | 1 | 316 | RoW | HSK42360 | Haisco Pharmaceutical Group Co., Ltd. | Solid Tumors | 08/26 | 07/27 | | |
NCT06428331: A Study of SKB518 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 150 | NA | SKB518 for injection, SKB518 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Advanced Solid Tumors | 06/26 | 06/26 | | |
| Recruiting | 1 | 42 | RoW | Anlotinib, Anlotinib dihydrochloride, Trastuzumab deruxtecan, DS-8201 | Fudan University | Breast Cancer | 12/26 | 06/27 | | |
BL-B01D1-104, NCT05470348: A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 36 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 06/25 | 12/25 | | |
NCT05394168: A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 12 | RoW | HLX53 | Shanghai Henlius Biotech | Advanced/Metastatic Solid Tumors | 12/24 | 03/25 | | |
| Recruiting | 1 | 170 | RoW | SPH7485 | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumor | 12/27 | 12/27 | | |
BL-M17D1-101, NCT06503783: A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | BL-M17D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 08/26 | 08/26 | | |
BL-B16D1-103, NCT06493864: A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors |
|
|
| Recruiting | 1 | 21 | RoW | BL-B16D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Breast Cancer, Solid Tumor | 07/26 | 07/26 | | |
NCT05657418: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer |
|
|
| Not yet recruiting | 1 | 106 | RoW | JS107, JS107 combination with Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Advanced Pancreatic Cancer | 09/24 | 12/24 | | |
NCT05360381: HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Active, not recruiting | 1 | 82 | RoW | HLX35 | Shanghai Henlius Biotech | Locally Advanced or Metastatic Solid Tumors, Squamous-cell Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
NCT06426680: A Study of the ILB-3101 in Patients with Advanced Solid Tumors |
|
|
| Recruiting | 1 | 240 | RoW | ILB-3101 | Innolake Biopharm | Advanced Solid Tumor | 12/25 | 03/26 | | |
NCT06718621: A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1 | 22 | RoW | BL-M08D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Solid Tumor | 12/26 | 06/27 | | |
NCT06710158: Study of SC-102 in Patients with Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 120 | RoW | SC-102 | Tianjin ConjuStar Biologics Co., Ltd. | Advanced Solid Cancers | 12/26 | 06/27 | | |
NCT05631964: Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors |
|
|
| Recruiting | 1 | 26 | RoW | BL-M07D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Digestive Tract Tumors, Other Solid Tumors | 06/25 | 12/25 | | |
NCT06609005: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients with Advanced Metastatic Castration Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 66 | US, RoW | INV-9956 | Shenzhen Ionova Life Sciences Co., Ltd. | Advanced Metastatic Castration Resistant Prostate Cancer | 04/26 | 03/27 | | |
NCT05787535: HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor |
|
|
| Recruiting | 1 | 17 | RoW | Fludarabine + Cyclophosphamide, HRYZ-T101 TCR-T Cell | HRYZ Biotech Co. | Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Oropharyngeal Cancer, Vagina Tumor, Carcinoma of Penis, Anal Carcinoma, Carcinoma of Vulva | 02/25 | 09/25 | | |
NCT05914376: Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors |
|
|
| Recruiting | 1 | 24 | RoW | Recombinant human IL-21-expressing oncolytic vaccinia virus injection, hV01 | Hangzhou Converd Co., Ltd. | Advanced Solid Tumors | 03/25 | 11/25 | | |
NCT05843305: A Study of BPI-452080 in Subjects With Solid Tumors |
|
|
| Not yet recruiting | 1 | 87 | RoW | BPI-452080 | Betta Pharmaceuticals Co., Ltd. | Solid Tumor, Renal Cell Carcinoma, Von Hippel-Lindau Disease | 03/25 | 10/25 | | |
NCT06094777: A Study of HY-0102 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | HY-0102 | Shanghai YingLi Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 06/25 | 12/25 | | |
| Recruiting | 1 | 20 | RoW | Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection | Fudan University, Cellular Biomedicine Group Ltd. | Cervical Cancer | 07/25 | 07/25 | | |
NCT04936178: A Study of NB003 in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 258 | Europe, US, RoW | NB003 tablets | Ningbo Newbay Technology Development Co., Ltd | Advanced Solid Tumor | 07/25 | 12/25 | | |
NCT05430373: GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors |
|
|
| Recruiting | 1 | 31 | RoW | GT101 | Grit Biotechnology | Solid Tumors, Adult | 08/25 | 12/25 | | |
NCT05942378: A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 30 | RoW | HRXG-K-1939, HRXG-K-1939 is a mRNA cancer vaccines, Adebrelimab | Fudan University | Advanced Solid Tumors | 09/25 | 12/25 | | |
NCT06064812: A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. |
|
|
| Recruiting | 1 | 99 | RoW | FWD1802, palbocilib | Forward Pharmaceuticals Co., Ltd. | Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage I, ER+ Breast Cancer | 11/25 | 02/26 | | |
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer |
|
|
| Recruiting | 1 | 20 | RoW | CT041 autologous CAR T-cell injection, Single Group Assignment | CARsgen Therapeutics Co., Ltd., Fudan University | Pancreatic Cancer | 12/26 | 12/26 | | |
